TAK-653
Cognition, Mood
Terminal half-life measured at 33.1-47.8 h across oral doses of 0.3-18 mg in healthy volunteers; 40 h is the midpoint. One of the few compounds in this section with real human pharmacokinetic data.
In short
- An investigational AMPA receptor positive allosteric modulator developed by Takeda for major depressive disorder.
- One of the very few compounds in the nootropic section with genuine published human pharmacokinetics: terminal half-life 33–48 hours.
- Phase 1 in 88 healthy volunteers showed good tolerability and, unlike ketamine, no dissociative effects.
- Efficacy in depression has not been established — Phase 1 measures safety and pharmacodynamics, not benefit.
- Not approved anywhere. Sold as a research chemical.
Structure
How it works
TAK-653 binds an allosteric site on the AMPA receptor and increases the receptor's response to glutamate without activating it directly. The distinguishing property described by Takeda is minimal intrinsic agonism — it amplifies signalling only where glutamate is already being released.
That matters because the ampakine class has historically been limited by excitotoxicity concerns: compounds that open AMPA channels indiscriminately risk excessive calcium influx. Strict agonist-dependence is the design feature intended to avoid that.
The proposed antidepressant rationale follows the ketamine literature, where downstream AMPA activation and BDNF-mediated synaptic changes are thought to drive rapid effects.
What the research shows
In healthy volunteers, transcranial magnetic stimulation showed increased cortical excitability, confirming target engagement in the human brain. Cerebrospinal fluid concentrations indicated rapid brain penetration.
Rodent studies reported antidepressant-like effects with a favourable safety margin relative to older ampakines.
No published Phase 2 efficacy result in depression is available as of this review. Reports of cognitive benefit in healthy people are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — Phase 1 single ascending dose, healthy volunteers | Single doses up to 18 mg were generally well tolerated | oral | Journal |
| Human — Phase 1 multiple ascending dose, healthy volunteers | Up to 9 mg once daily was generally well tolerated | oral | Journal |
| Human — pharmacokinetics across 0.3–18 mg | Terminal half-life 33.1–47.8 h; Tmax 1.25–5 h | oral | ClinicalTrials.gov |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 0.5–2 mg daily | oral |
The Phase 1 tolerability ceiling is not an efficacy dose and not a recommendation — it is the highest amount at which a monitored trial saw acceptable safety in screened, healthy participants. With a 33–48 hour half-life, daily dosing accumulates for roughly a week before levels plateau.
Handling and storage
Oral, supplied as capsules or powder in the research-chemical market. The long half-life means daily dosing accumulates and a change takes about a week to fully express — evaluating an effect after two days is measuring a rising curve, not a steady state.
Side effects
Phase 1 reported good tolerability with no dissociative effects, which was a notable contrast with ketamine and a stated goal of the programme.
What that does not cover: long-term use, use outside the screened trial population, and interactions. Phase 1 enrols healthy young adults under monitoring.
The theoretical class risk is excitotoxicity and seizure threshold reduction. TAK-653 was specifically engineered to minimise this, and no seizures were reported in the published Phase 1, but the class history is why this is worth naming.
Combinations
No interaction data exists for combinations with other nootropics. The pharmacologically obvious caution is combining it with anything else affecting glutamatergic signalling or seizure threshold, where the effects would be additive and unstudied.
Research status
First-in-human trial (NCT02561156) enrolled 88 healthy subjects. A separate TMS pharmacodynamic study (NCT03792672) demonstrated cortical target engagement. Preclinical work is published in Scientific Reports and Neuropharmacology.
Development for major depressive disorder has not produced a published positive Phase 2 as of this review.
Legal status
Not approved in any jurisdiction. Investigational compound sold in the research-chemical market labelled not for human consumption. Not a controlled substance in most jurisdictions, which is a statement about scheduling rather than about safety or legality of sale for consumption.
WADA status
Not specifically named on the WADA Prohibited List as of this review date. Note that WADA's S0 category covers any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use — an investigational compound like this falls under S0 and should be treated as prohibited in sport.
Conclusion
TAK-653 is unusual in this section for having real human data: measured pharmacokinetics, demonstrated brain penetration, and confirmed target engagement. That makes it far better characterised than 9-Me-BC or Sunifiram.
It also has no demonstrated efficacy for anything, in anyone. Well-characterised and effective are different claims, and the first does not imply the second.
Sources
- [1]CNS effects of TAK-653 in healthy volunteers (Translational Psychiatry, 2022)Journal
- [2]TAK-653 first-in-human escalating dose study protocol (NCT02561156)ClinicalTrials.gov
- [3]TAK-653 TMS pharmacodynamic study (NCT03792672)ClinicalTrials.gov
- [4]Agonist-dependent AMPA-R activation of TAK-653 (Scientific Reports, 2021)Journal
- [5]PubChem CID 56655833PubChem
- [6]WADA Prohibited List (current)WADA
Track your own TAK-653 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.